MISTAKES IN OUTPATIENT NEUROLOGICAL PRACTICE. PART II

Abstract

In the second part of this article continues the analysis of some errors in the national outpatient practice in the diagnosis and treatment of neurological diseases. Given the current data about the results of scientific and clinical studies on the efficiency cerebroprotective, nootropic and vasoactive drugs in the treatment of stroke, discirculatory encephalopathy and vascular dementia. The mainstay of treatment of chronic ischemia of the brain is early detection and correction of risk factors for cardiovascular diseases. Overdiagnosis of cerebrovascular diseases and their role in the development of cognitive disorders lead to erroneous use of drugs with unproven efficacy.

Keywords

neurological mistakes / stroke / chronic ischemia of the brain / vascular dementia

References

[1] Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack. The European Stroke Organization (ESO). - 2008. - 120 p.

[2] Jauch E. C., Saver J. L., Adams H. P. et al. Guidelines for the early management of patients with acute ischemic stroke // Stroke. - 2013. - Vol. 44. - P. 870-947.

[3] Anderson D., Larson D., Bluhm J. et al. Diagnosis and Initial Treatment of Ischemic Stroke. Updated July 2012. Institute for Clinical Systems Improvement. - 122 p. - www. icsi.org. - Последнее посещение сайта 01.02.2015 г.

[4] Shuaib A., Lees K. R., Lyden P. et al. Nxy-059 for the treatment of acute ischemic stroke // N. Engl. J. Med. - 2007. - Vol. 357. - P. 562-571.

[5] Muir K. W., Lees K. R., Ford I., Davis S. Magnesium for acute stroke (intravenous magnesium efficacy in stroke trial): Randomised controlled trial // Lancet. - 2004. - Vol. 363. - P. 439-445.

[6] Dаvаlоs А., Аlvаrеz-Sаbin J., Саstillо J. еt аl. Сitiсоlinе in thе trеаtmеnt оf асиtе isсhаеmiс strоке: аn intеrnаtiоnаl, rаndоmisеd, mиltiсеntrе, рlасеbо-соntrоllеd stиdу (IСТUS triаl) // Lаnсеt. - 2012. - Vоl. 380. - Р. 349-357.

[7] OCollins V. E., Macleod M. R., Donnan G. A. et al. Experimental treatments in acute stroke // Ann. Neurol. - 2006. - Vol. 59. - P. 467-477.

[8] Wheble P. C., Sena E. S., Macleod M. R. A systematic review and meta-analysis of the efficacy of piracetam and piracetam-like compounds in experimental stroke // Cerebrovasc. Dis. - 2008. - Vol. 25. - № 1-2. - P. 5-11.

[9] Wahlgren N. G., Ahmed N. Neuroprotection in cerebral ischaemia: facts and fancies: the need for new approaches // Cerebrovasc. Dis. - 2004. - Vol. 17. - Suppl. 1. - P. 153-166.

[10] Donnan G. A. The 2007 Feinberg lecture: a new road map for neuroprotection // Stroke. - 2008. - Vol. 39. - P. 242.

[11] Savitz S. I., Fisher M. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials // Ann. Neurol. - 2007. - Vol. 61. - P. 396-402.

[12] Неотложная помощь больным с острыми нарушениями мозгового кровообращения на догоспитальном этапе в Санкт-Петербурге. Методические рекомендации, утвержденные Комитетом по здравоохранению Правительства СПб. - СПб., 2008. - 16 с. - http://www.mexifin.ru. - Последнее посещение сайта 01.02.2015 г.

[13] Heiss W. D., Brainin M., Bornstein N. M. et al. Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial // Stroke. - 2012. - Vol. 43. - № 3. - P. 630-636.

[14] Bath P. M. Theophylline, aminophylline, caffeine and analogues for acute ischaemic stroke (Review). The Cochrane Library. - 2004. - Issue 3. - P. 3. - http://www.thecochranelibrary.com. - Последнее посещение сайта 01.02.2015 г.

[15] Ricci S., Celani M. G., Cantisani T. A., Righetti E. Piracetam for acute ischaemic stroke (Review). The Cochrane Library. - 2012. - Issue 9. - P. 3. - http://www.thecochranelibrary.com. - Последнее посещение сайта 01.02.2015 г.

[16] Bereczki D., Fekete I. Vinpocetine for acute ischaemic stroke (Review). The Cochrane Library. - 2008. - Issue 1. - P. 3. - http://www.thecochranelibrary.com.

[17] Bath P. M., Bath-Hextall F. J. Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke (Review). The Cochrane Library. - 2004. - Issue 3. - P. 3. - http://www.thecochranelibrary.com. - Последнее посещение сайта 01.02.2015 г.

[18] Скворцова В. И., Боцина А. Ю., Кольцова К. В. и соавт. Артериальная гипертония и головной мозг // Журнал неврологии и психиатрии им. С. С. Корсакова. - 2006. - № 10. - С. 68-78.

[19] Скворцова В. И., Соколов К. В., Шамалов Н. А. Артериальная гипертония и цереброваскулярные нарушения // Журнал неврологии и психиатрии им. С. С. Корсакова. - 2006. - № 11. - С. 57-64.

[20] Kemeny V., Molnar S., Andrejkovics M. et al. Acute and chronic effects of vinpocetine on cerebral hemo-dynamics and neuropsychological performance in multi-infarct patients // J. Clin. Pharmacol. - 2005. - Vol. 45. - № 9. - P. 1048-1054.

[21] Bahar-Fuchs A., Clare L., Woods B. Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer's disease and vascular dementia (Review). The Cochrane Library. - 2013. - Issue 6. - P. 103. - http:// www.thecochranelibrary.com. - Последнее посещение сайта 01.02.2015 г.

[22] Gorelick Ph. B., Angelo Scuteri A., Black S. E. et al. Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association /American Stroke Association // Stroke. - 2011. - Vol. 42. - P. 2672-2713.

[23] Lobo A., Launer L. J., Fratiglioni L. et al. Neurologic Diseases in the Elderly Research Group. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts // Neurology. - 2000. - Vol. 54. - Suppl 5. - P. 4-9.

[24] Яхно Н. Н., Захаров В. В., Локшина А. Б. и соавт. Деменции: руководство для врачей. - М.: МЕДпресс-информ, 2011. - 272 с.

[25] Kivipelto M., Ngandu T., Fratiglioni L. et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease // Arch. Neurol. - 2005. - Vol. 62. - P. 1556-1560.

[26] Mott M., Pahigiannis K., Koroshetz W. Small Blood Vessels: Big Health Problems: National Institute of Neurological Disorders and Stroke Update // Stroke. - 2014. - Vol. 45. - P. 257-258.

[27] DasR. R., SeshadriS., Beiser A. S. et al. Prevalence and correlates of silent cerebral infarcts in the Framingham offspring study // Stroke. - 2008. - Vol. 39. - P. 2929-2935.

[28] Pendlebury S. T., Rothwell P. M. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis // Lancet Neurol. - 2009. - Vol. 8. - P. 1006-1018.

[29] Jefferson A. L., Himali J. J., Beiser A. S. et al. Cardiac index is associated with brain aging: the Framingham Heart Study // Circulation. - 2010. - Vol. 122. - P. 690-697.

[30] Lees R., Selvarajah J., Fenton C. et al. Test Accuracy of Cognitive Screening Tests for Diagnosis of Dementia and Multidomain Cognitive Impairment in Stroke // Stroke. - 2014. - Vol. 45. - P. 3008-3018.

[31] Harrison J. K., Fearon P., Noel-Storr A. H. et al. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a general practice (primary care) setting (Review). The Cochrane Library. - 2014. - Issue 7. - P. 3. - http://www.thecochranelibrary.com. - Последнее посещение сайта 01.02.2015 г.

[32] Yokomizo J. E., Simon S. S., Bottino C. M. Cognitive screening for dementia in primary care: a systematic review // Int. Psychogeriatr. - 2014. - Vol. 26. - № 11. - P. 1783-1804.

[33] Knopman D., Boland L. L., Mosley T. et al. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Cardiovascular risk factors and cognitive decline in middle-aged adults // Neurology. - 2001. - Vol. 56. - P. 42-48.

[34] Small G. W. Vascular dementia: galantamine (Reminyl) as an emerging therapeutic option // Acta Neurol. Scand. - 2002. - Vol. 106. - Suppl. 178. - P. 4-5.

[35] Wong C. L., Bansback N., Lee P. E., Anis A. H. Cost-effectiveness: cholinesterase inhibitors and memantine in vascular dementia // Can. J. Neurol. Sci. - 2009. - Vol. 36. - № 6. - P. 735-739.

[36] Roman G. C., Salloway S., Black S. E. et al. Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size // Stroke. - 2010. - Vol. 41. - № 6. - P. 1213-1221.

[37] Russ T. C., Morling J. R. Cholinesterase inhibitors for mild cognitive impairment (Review). The Cochrane Library. - 2012. - Issue 9. - P. 3. - http://www.thecochranelibrary.com. - Последнее посещение сайта 01.02.2015 г.

[38] Bowler J. V. Vascular cognitive impairment // Stroke. - 2004. - Vol. 35. - № 2. - P. 386-388.

[39] DeKosky S. T., Williamson J. D., Fitzpatrick A. L. et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial // J. American Medical Association. - 2008. - Vol. 300. - № 19. - P. 2253-2262.

[40] Flicker L., Grimley Evans J. Piracetam for dementia or cognitive impairment (Review). The Cochrane Library. - 2004. - Issue 1. - P. 3. - http://www.thecochranelibrary.com. - Последнее посещение сайта 01.02.2015 г.

[41] Chen N., Yang M., Guo J., Zhou M. et al. Cerebrolysin for vascular dementia (Review). The Cochrane Library. - 2013. - Issue 1. - P. 3. - http://www.thecochranelibrary.com. - Последнее посещение сайта 01.02.2015 г.

[42] Szatmari S., Whitehouse P. Vinpocetine for cognitive impairment and dementia (Review). The Cochrane Library. - 2003. - Issue 1. - P. 3. - http://www.thecochranelibrary.com. - Последнее посещение сайта 01.02.2015 г.

[43] Klugman A., Sauer J., Tabet N., Howard R. Alpha lipoic acid for dementia (Review). The Cochrane Library. - 2004. - Issue 1. - P. 3. - http://www.thecochranelibrary.com. - Последнее посещение сайта 01.02.2015 г.

[44] Wu S., Liang J., Miao D. Physical activity and cognitive function in Alzheimer disease // JAMA. - 2009. - Vol. 301. - P. 273.

[45] Liu-Ambrose T., Eng J. J., Boyd L. A. et al. Promotion of the mind through exercise (PROMoTE): a proof-of-concept randomized controlled trial of aerobic exercise training in older adults with vascular cognitive impairment // BMC Neurol. - 2010. - Vol. 10. - P. 14.

[46] Cotman C. W., Berchtold N. C., Christie L. A. Exercise builds brain health: key roles of growth factor cascades and inflammation // Trends Neurosci. - 2007. - Vol. 30. - P. 464-472.

[47] Beydoun M. A., Beydoun H. A., Wang Y. Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis // Obes. Rev. - 2008. - Vol. 9. - P. 204-218.

[48] Kalmijn S., van Boxtel M. P., Ocke M. et al. Dietary intake of fatty acids and fish in relation to cognitive performance at middle age // Neurology. - 2004. - Vol. 62. - P. 275-280.

[49] Beydoun M. A., Kaufman J. S., Satia J. A. et al. Plasma n-3 fatty acids and the risk of cognitive decline in older adults: the Atherosclerosis Risk in Communities Study // Am. J. Clin. Nutr. - 2007. - Vol. 85. - P. 1103-1111.

[50] Woods B., Aguirre E., Spector A. E., Orrell M. Cognitive stimulation to improve cognitive functioning in people with dementia (Review). The Cochrane Library. - 2012. - Issue 2. - P. 3. - http://www.thecochranelibrary.com. - Последнее посещение сайта 01.02.2015 г.

RIGHTS & PERMISSIONS

Kandyba D.V.